Literature DB >> 21422989

Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Sravana K Chennupati1, Andrew Quon, Aya Kamaya, Reetesh K Pai, Trang La, Trevor E Krakow, Edward Graves, Albert C Koong, Daniel T Chang.   

Abstract

PURPOSE: To investigate whether before and after chemoradiotherapy (CRT) positron emission tomography (PET) predict for pathologic response after preoperative CRT in patients with locally advanced rectal adenocarcinoma.
METHODS: Thirty-five patients who underwent pre-CRT and post-CRT PET scans before surgery were included. All patients were staged with endoscopic ultrasound or high resolution CT. CRT was given with 50.4 Gy at 1.8 Gy per fraction and concurrent 5-fluorouracil-based chemotherapy. Surgery occurred at a median of 46 days (range, 27 to 112 d) after completing CRT. The maximum standardized uptake value (SUV(max)) and the metabolic tumor volume (MTV) using various minimum SUV thresholds (2, 2.5, 3) on the PET scans (MTV(2.0), MTV(2.5), MTV(3.0)) were determined. Post-CRT PET scans were done 3 to 5 weeks after completion of CRT. Pathologic response was assessed using the tumor regression grade (TRG) scale. Patients with complete or near-complete response (TRG=0 to 1) were considered pathologic responders. The pre-CRT and post-CRT PET scan SUV(max) and MTV values were correlated with TRG. The ΔSUV(max) and ΔMTV were correlated with TRG.
RESULTS: No correlation was seen with SUV(max) (P=0.99), MTV(2.0) (P=0.73), MTV(2.5) (P=0.73), or MTV(3.0) (P=0.31) on the pre-CRT PET between pathologic responders versus nonresponders. No correlation was noted between SUV(max) (P=0.49), MTV(2.0) (P=0.73), MTV(2.5) (P=0.49), or MTV(3.0) (P=0.31) on the post-CRT PET scan and pathologic response. Finally, the ΔSUV(max) (P=0.32), ΔMTV(2.0) (P=0.99), ΔMTV(2.5) (P=0.31), ΔMTV(3.0) (P=0.31) did not correlate with pathologic response.
CONCLUSIONS: Changes seen on PET have limited value in predicting for pathologic response of rectal cancer after preoperative neoadjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21422989     DOI: 10.1097/COC.0b013e3182118d12

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  11 in total

Review 1.  How Should Imaging Direct/Orient Management of Rectal Cancer?

Authors:  Jemma Bhoday; Svetlana Balyasnikova; Anita Wale; Gina Brown
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

2.  Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy.

Authors:  Anna Margherita Maffione; Alice Ferretti; Gaia Grassetto; Elena Bellan; Carlo Capirci; Sotirios Chondrogiannis; Marcello Gava; Maria Cristina Marzola; Lucia Rampin; Claudia Bondesan; Patrick M Colletti; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-16       Impact factor: 9.236

3.  The role of positron emission tomography/CT imaging in head and neck cancer patients after radical chemoradiotherapy.

Authors:  J M Sherriff; B Ogunremi; S Colley; P Sanghera; A Hartley
Journal:  Br J Radiol       Date:  2012-06-27       Impact factor: 3.039

4.  Tumor SUVmax Normalized to Liver Uptake on (18)F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Authors:  Jihyun Park; Kyoung Jin Chang; Young Seok Seo; Byung Hyun Byun; Joon Ho Choi; Hansol Moon; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2014-08-01

5.  The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy.

Authors:  Lucia Leccisotti; Maria Antonietta Gambacorta; Chiara de Waure; Antonella Stefanelli; Brunella Barbaro; Fabio Maria Vecchio; Claudio Coco; Roberto Persiani; Antonio Crucitti; Antonino Pio Tortorelli; Alessandro Giordano; Vincenzo Valentini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-17       Impact factor: 9.236

6.  Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PET.

Authors:  Mathieu Hatt; Ruud van Stiphout; Adrien le Pogam; Guido Lammering; Dimitris Visvikis; Philippe Lambin
Journal:  Acta Oncol       Date:  2012-08-08       Impact factor: 4.089

Review 7.  Current approaches and challenges for monitoring treatment response in colon and rectal cancer.

Authors:  Elizabeth McKeown; Daniel W Nelson; Eric K Johnson; Justin A Maykel; Alexander Stojadinovic; Aviram Nissan; Itzhak Avital; Björn Ldm Brücher; Scott R Steele
Journal:  J Cancer       Date:  2014-01-01       Impact factor: 4.207

8.  Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal Cancer.

Authors:  Jessica A Smith; Aaron T Wild; Aatur Singhi; Siva P Raman; Haoming Qiu; Rachit Kumar; Amy Hacker-Prietz; Ralph H Hruban; Ihab R Kamel; Jonathan Efron; Elizabeth C Wick; Nilofer S Azad; Luis A Diaz; Yi Le; Elwood P Armour; Susan L Gearhart; Joseph M Herman
Journal:  Int J Surg Oncol       Date:  2012-07-08

Review 9.  New Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal Cancer.

Authors:  Nam Kyu Kim; Hyuk Hur
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

10.  Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer?

Authors:  Letizia Deantonio; Angela Caroli; Erinda Puta; Daniela Ferrante; Francesco Apicella; Lucia Turri; Gianmauro Sacchetti; Marco Brambilla; Marco Krengli
Journal:  Radiat Oncol       Date:  2018-10-25       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.